What is Cleara Biotech?
Cleara Biotech is a biopharmaceutical research and development firm dedicated to discovering and advancing therapies for cancer and chronic diseases. The company's core innovation lies in its proprietary platform technology, which focuses on the selective elimination of cellular senescence subtypes. By developing peptide-based therapeutics targeting specific senescence types, Cleara aims to address critical unmet needs in areas such as metastatic and mutant-p53 cancers. Their approach emphasizes precision medicine, leveraging associated biomarkers to create highly targeted anti-senescence treatments. The company's lead programs, CL04177 and CL04183, are poised to enter clinical development, representing a significant step forward in niche-specific therapeutic strategies.
How much funding has Cleara Biotech raised?
Cleara Biotech has raised a total of $2.5M across 1 funding round:
Angel/Seed
$2.5M
Angel/Seed (2022): $2.5M with participation from Curie Capital
Key Investors in Cleara Biotech
Curie Capital
Curie Capital is a venture capital firm based in Amsterdam, specializing in early-stage investments in the life sciences sector, particularly in biotechnology, pharmaceuticals, and medical technology. Founded in 2018, the firm focuses on Seed and Series A stage companies that are compliant with Dutch regulations and have not raised more than 3.5 million in equity. Curie Capital not only provides capital but also offers extensive support and expertise to help portfolio companies grow and succeed. Their investment strategy emphasizes fostering innovation and sustainability in the medical field.
What's next for Cleara Biotech?
With the recent major strategic investment, Cleara Biotech is well-positioned to accelerate the clinical development of its lead therapeutic candidates. This funding is expected to fuel the progression of CL04177 and CL04183 through rigorous testing phases, bringing them closer to patient application. The company's focus on precision medicine and the selective elimination of senescent cells aligns with current trends in oncology and chronic disease management, suggesting a strong market potential. Future endeavors will likely involve expanding the pipeline and potentially forging strategic partnerships to further enhance the reach and impact of their innovative platform technology.
See full Cleara Biotech company page
